A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry

A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry

Abstract Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody that targets the IL-6 receptor. TCZ found to be efficacious and has a good tolerated safety profile in rheumatoid arthritis (RA) patients. The aim of this study was to describe the disease activity and retention rate in Turkis...

Full description

Bibliographic Details
Main Authors: Ayten Yazici, Özlem Özdemir Işık, Ediz Dalkılıç, Süleyman Serdar Koca, Yavuz Pehlivan, Soner Şenel, Nevsun Inanc, Servet Akar, Sema Yılmaz, Özgül Soysal Gündüz, Ayse Cefle, Ömer Fatih Karakaş, Fatos Onen
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-26106-0

Internet

https://doi.org/10.1038/s41598-022-26106-0

Similar Items